cbdMD, Inc. (YCBD) DCF Valuation
- ✓ Entièrement Modifiable: Adapté À Vos Besoins Dans Excel Ou Sheets
- ✓ Conception Professionnelle: Modèles Fiables Et Conformes Aux Normes Du Secteur
- ✓ Pré-Construits Pour Une Utilisation Rapide Et Efficace
- ✓ Aucune Expertise N'Est Requise; Facile À Suivre
cbdMD, Inc. (YCBD) Bundle
Looking to assess cbdMD, Inc.'s intrinsic value? Our (YCBD) DCF Calculator integrates real-world data with comprehensive customization features, enabling you to adjust projections and enhance your investment choices.
Discounted Cash Flow (DCF) - (USD MM)
Year | AY1 2020 |
AY2 2021 |
AY3 2022 |
AY4 2023 |
AY5 2024 |
FY1 2025 |
FY2 2026 |
FY3 2027 |
FY4 2028 |
FY5 2029 |
---|---|---|---|---|---|---|---|---|---|---|
Revenue | 41.9 | 44.5 | 35.4 | 24.2 | 19.5 | 16.3 | 13.6 | 11.4 | 9.5 | 8.0 |
Revenue Growth, % | 0 | 6.2 | -20.41 | -31.77 | -19.35 | -16.33 | -16.33 | -16.33 | -16.33 | -16.33 |
EBITDA | -16.9 | -22.0 | -15.5 | -7.5 | -1.5 | -5.6 | -4.7 | -3.9 | -3.3 | -2.7 |
EBITDA, % | -40.26 | -49.48 | -43.72 | -30.92 | -7.67 | -34.41 | -34.41 | -34.41 | -34.41 | -34.41 |
Depreciation | 1.9 | 2.3 | 3.0 | 2.9 | 1.8 | 1.3 | 1.1 | .9 | .8 | .6 |
Depreciation, % | 4.54 | 5.07 | 8.39 | 12.12 | 9.34 | 7.89 | 7.89 | 7.89 | 7.89 | 7.89 |
EBIT | -18.8 | -24.3 | -18.4 | -10.4 | -3.3 | -6.9 | -5.8 | -4.8 | -4.0 | -3.4 |
EBIT, % | -44.8 | -54.54 | -52.11 | -43.04 | -17.02 | -42.3 | -42.3 | -42.3 | -42.3 | -42.3 |
Total Cash | 15.1 | 27.4 | 7.7 | 1.8 | 2.5 | 4.6 | 3.8 | 3.2 | 2.7 | 2.2 |
Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
Account Receivables | .9 | 1.1 | 1.4 | 1.2 | 1.0 | .6 | .5 | .4 | .4 | .3 |
Account Receivables, % | 2.18 | 2.5 | 4.09 | 5.03 | 5.05 | 3.77 | 3.77 | 3.77 | 3.77 | 3.77 |
Inventories | 4.6 | 5.0 | 4.3 | 4.1 | 2.4 | 2.1 | 1.7 | 1.4 | 1.2 | 1.0 |
Inventories, % | 10.99 | 11.29 | 12.02 | 16.78 | 12.14 | 12.64 | 12.64 | 12.64 | 12.64 | 12.64 |
Accounts Payable | 2.9 | 3.0 | 2.0 | 1.9 | 1.5 | 1.1 | 1.0 | .8 | .7 | .6 |
Accounts Payable, % | 6.81 | 6.7 | 5.75 | 7.89 | 7.91 | 7.01 | 7.01 | 7.01 | 7.01 | 7.01 |
Capital Expenditure | -1.3 | -2.3 | -.7 | -.3 | -.3 | -.4 | -.4 | -.3 | -.2 | -.2 |
Capital Expenditure, % | -3.15 | -5.27 | -1.95 | -1.23 | -1.49 | -2.62 | -2.62 | -2.62 | -2.62 | -2.62 |
Tax Rate, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EBITAT | -20.9 | -23.4 | -19.5 | -10.4 | -3.3 | -6.8 | -5.7 | -4.8 | -4.0 | -3.4 |
Depreciation | ||||||||||
Changes in Account Receivables | ||||||||||
Changes in Inventories | ||||||||||
Changes in Accounts Payable | ||||||||||
Capital Expenditure | ||||||||||
UFCF | -23.0 | -23.9 | -17.7 | -7.5 | -.2 | -5.7 | -4.8 | -4.0 | -3.3 | -2.8 |
WACC, % | 4.46 | 4.3 | 4.46 | 4.46 | 4.46 | 4.43 | 4.43 | 4.43 | 4.43 | 4.43 |
PV UFCF | ||||||||||
SUM PV UFCF | -18.4 | |||||||||
Long Term Growth Rate, % | 2.00 | |||||||||
Free cash flow (T + 1) | -3 | |||||||||
Terminal Value | -117 | |||||||||
Present Terminal Value | -94 | |||||||||
Enterprise Value | -113 | |||||||||
Net Debt | 1,270 | |||||||||
Equity Value | -1,383 | |||||||||
Diluted Shares Outstanding, MM | 4 | |||||||||
Equity Value Per Share | -320.59 |
What You Will Receive
- Comprehensive Financial Model: cbdMD’s actual data facilitates accurate DCF valuation.
- Complete Forecasting Control: Modify revenue growth, profit margins, WACC, and other essential factors.
- Real-Time Calculations: Automatic updates allow you to view results instantly as you make adjustments.
- Professional-Grade Template: A polished Excel file crafted for high-quality valuation.
- Adaptable and Reusable: Designed for versatility, enabling repeated use for in-depth forecasts.
Key Features
- Comprehensive YCBD Data: Pre-filled with cbdMD's historical performance metrics and future growth forecasts.
- Fully Customizable Inputs: Modify revenue growth rates, profit margins, discount rates, tax assumptions, and capital investments.
- Dynamic Valuation Model: Automatic recalculations of Net Present Value (NPV) and intrinsic value based on your customized inputs.
- Scenario Testing: Develop various forecasting scenarios to assess different valuation results.
- User-Friendly Design: Intuitive, organized layout suitable for both professionals and novices.
How It Works
- Step 1: Download the Excel file for cbdMD, Inc. (YCBD).
- Step 2: Examine cbdMD’s pre-filled financial data and projections.
- Step 3: Adjust key inputs such as revenue growth, WACC, and tax rates (highlighted cells).
- Step 4: Observe the DCF model refresh in real-time as you modify assumptions.
- Step 5: Evaluate the outputs and leverage the findings for investment choices.
Why Choose This Calculator for cbdMD, Inc. (YCBD)?
- Accurate Data: Current cbdMD financials provide trustworthy valuation outcomes.
- Customizable: Modify essential parameters such as growth rates, WACC, and tax rates to fit your forecasts.
- Time-Saving: Built-in calculations save you from starting from the ground up.
- Professional-Grade Tool: Tailored for investors, analysts, and consultants in the CBD industry.
- User-Friendly: Simple design and clear instructions ensure accessibility for all users.
Who Should Use cbdMD, Inc. (YCBD)?
- Health Enthusiasts: Discover the benefits of CBD products and how they can enhance wellness.
- Researchers: Utilize data and insights for studies related to CBD and its effects.
- Consumers: Evaluate product options to find the best CBD solutions for personal needs.
- Retailers: Access a reliable source of high-quality CBD products to offer in your store.
- Investors: Analyze market trends and performance metrics to make informed decisions regarding cbdMD, Inc. (YCBD).
What the Template Contains
- Pre-Filled Data: Includes cbdMD, Inc.'s historical financials and forecasts.
- Discounted Cash Flow Model: Editable DCF valuation model with automatic calculations.
- Weighted Average Cost of Capital (WACC): A dedicated sheet for calculating WACC based on custom inputs.
- Key Financial Ratios: Analyze cbdMD, Inc.'s profitability, efficiency, and leverage.
- Customizable Inputs: Edit revenue growth, margins, and tax rates with ease.
- Clear Dashboard: Charts and tables summarizing key valuation results.